Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year
13 Novembro 2023 - 9:00AM
Business Wire
Castle also earns national recognition through
three Top Workplaces Culture Excellence Awards — Employee
Appreciation, Employee Well-Being and Professional Development
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that it has been named a Houston Chronicle Top Workplace
for the third year in a row and awarded three new Culture
Excellence awards, recognizing the Company in the areas of Employee
Appreciation, Employee Well-Being and Professional Development.
“Our Castle team is the heart and soul of our organization and
the foundation of our strong company culture,” said Derek Maetzold,
president and chief executive officer at Castle Biosciences. “I am
incredibly grateful to our outstanding employees who continue to
deliver on our commitment to improving patient care through
innovative diagnostics.”
The Top Workplaces program starts with capturing employee
feedback on what matters most about a company’s culture. Award
winners are determined through an anonymous third-party survey,
administered by Energage, that measures 15 drivers of company
culture, as well as other insights related to company leadership
and employee engagement.
The addition of these recent accolades brings the Company’s
total 2023 Top Workplaces awards to 12, which include two regional
awards for Houston and Arizona and ten national awards: Top
Workplaces USA, Top Workplaces Industry (Healthcare, ranking third
out of 84 firms) and Top Workplaces Culture Excellence in
Innovation, Work-Life Flexibility, Compensation & Benefits,
Leadership, Purpose & Values, Employee Appreciation, Employee
Well-Being and Professional Development.
The complete list of 2023 Houston Chronicle Top Workplaces can
be viewed here. Additional information regarding the Cultural
Excellence Awards is available on the Top Workplaces website.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq,
TissueCypher and IDgenetix are trademarks of Castle Biosciences,
Inc.
About Energage
Making the world a better place to work together.™
Energage is a purpose-driven company that helps organizations
turn employee feedback into useful business intelligence and
credible employer recognition through Top Workplaces. Built on 17
years of culture research and the results from 27 million employees
surveyed across more than 70,000 organizations, Energage delivers
the most accurate competitive benchmark available. With access to a
unique combination of patented analytic tools and expert guidance,
Energage customers lead the competition with an engaged workforce
and an opportunity to gain recognition for their people-first
approach to culture. For more information or to nominate your
organization, visit energage.com or topworkplaces.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231113638118/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024